Stellar Biotechnologies Inc(NASDAQ:SBOT) announced the earnings results for Fiscal Year 2016 and Q3. The results came in during Pre-market on Aug 9, 2016. Earnings per share were $-0.14.
Stellar Biotechnologies Inc. (Stellar) is a biotechnology company. The Company is engaged in the aquaculture research and development manufacture and commercialization of Keyhole Limpet Hemocyanin (KLH) protein. KLH is a high molecular weight and immune-stimulating protein. It operates under the brand name Stellar KLH. Its products include Stellar KLH protein in various grades formulations and configurations for both clinical and preclinical applications. Stellar KLH can be used for therapeutic vaccine conjugation as a carrier molecule in immunotherapies and as an immune stimulant in immunotoxicology applications. KLH can be used as an active pharmaceutical ingredient and combined with a disease-targeting agent to create immunotherapies targeting cancer immune disorders Alzheimer’s disease and inflammatory diseases or it can be used as a finished injectable product in the immunodiagnostic market for measuring immune response in patients and research settings.